<bill session="116" type="h" number="5882" updated="2022-02-08T23:20:34Z">
  <state datetime="2020-02-12">REFERRED</state>
  <status>
    <introduced datetime="2020-02-12"/>
  </status>
  <introduced datetime="2020-02-12"/>
  <titles>
    <title type="display">GENE Therapy Payment Act</title>
    <title type="official" as="introduced">To amend title XIX of the Social Security Act to provide States with the option under the Medicaid program to pay for covered outpatient drugs through risk-sharing value-based agreements, and for other purposes.</title>
    <title type="short" as="introduced">GENE Therapy Payment Act</title>
    <title type="short" as="introduced">Generating Effective and Novel Evidence for Therapy Payment Act</title>
  </titles>
  <sponsor bioguide_id="S001180"/>
  <cosponsors>
    <cosponsor bioguide_id="B001287" joined="2020-02-12"/>
    <cosponsor bioguide_id="C001121" joined="2020-02-12"/>
    <cosponsor bioguide_id="K000376" joined="2020-02-12"/>
    <cosponsor bioguide_id="M001198" joined="2020-02-12"/>
    <cosponsor bioguide_id="M001190" joined="2020-02-12"/>
    <cosponsor bioguide_id="S001183" joined="2020-02-12"/>
  </cosponsors>
  <actions>
    <action datetime="2020-02-12">
      <text>Introduced in House</text>
    </action>
    <action datetime="2020-02-12" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="19" relation="unknown"/>
    <bill session="116" type="s" number="2543" relation="unknown"/>
    <bill session="116" type="s" number="4199" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Appropriations"/>
    <term name="Congressional oversight"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug therapy"/>
    <term name="Genetics"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Home and outpatient care"/>
    <term name="Intergovernmental relations"/>
    <term name="Manufacturing"/>
    <term name="Medicaid"/>
    <term name="Prescription drugs"/>
    <term name="State and local government operations"/>
  </subjects>
  <amendments/>
  <summary date="2021-01-09T00:40:04Z" status="Introduced in House">Generating Effective and Novel Evidence for Therapy Payment Act or the GENE Therapy Payment Act

This bill allows state Medicaid programs to pay for certain gene therapy drugs through risk-sharing value-based payment agreements with drug manufacturers. The bill applies to covered outpatient drugs that provide potentially curative treatment for serious or life-threatening rare diseases or conditions after not more than three administrations.</summary>
</bill>
